US20070191815A1 - Biosynchronous transdermal drug delivery - Google Patents
Biosynchronous transdermal drug delivery Download PDFInfo
- Publication number
- US20070191815A1 US20070191815A1 US11/162,517 US16251705A US2007191815A1 US 20070191815 A1 US20070191815 A1 US 20070191815A1 US 16251705 A US16251705 A US 16251705A US 2007191815 A1 US2007191815 A1 US 2007191815A1
- Authority
- US
- United States
- Prior art keywords
- drug
- human
- animal
- timing
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0266—Shape memory materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3337—Controlling, regulating pressure or flow by means of a valve by-passing a pump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
Definitions
- the present invention relates, in general, to controlled drug delivery methods and systems, and, more specifically, to systems and methods for biosynchronous transdermal drug delivery in which drugs, pharmaceuticals, and other bioactive substances are delivered transdermally into a body in a manner that is synchronized with biological processes and/or biological rhythms so as to improve performance of the substance in the body.
- Instantaneous release refers to systems that make the active ingredient available immediately after administration to the biosystem of the host.
- Instantaneous release systems include continuous or pulsed intravenous infusion or injections. Such systems provide a great deal of control because administration can be both instantaneously started and stopped and the delivery rate can be controlled with great precision. However, the administration is undesirably invasive as they involve administration via a puncture needle or catheter.
- Dellayed release refers to systems in which the active ingredient made available to the host at some time after administration. Such systems include oral as well as injectable drugs in which the active ingredient is coated or encapsulated with a substance that dissolves at a known rate so as to release the active ingredient after the delay.
- Sustained Release generally refers to release of active ingredient such that the level of active ingredient available to the host is maintained at some level over a period of time.
- sustained release systems are difficult to control and exhibit variability from patient to patient. Due to the adsorption through the gastrointestinal tract, drug concentrations rise quickly in the body when taking a pill, but the decrease is dependent on excretion and metabolism, which can not be controlled. In addition, the adsorption through the gastrointestinal tract in many cases leads to considerable side effects (such as ulcers), and can severely damage the liver.
- Transdermal drug delivery has developed primarily for sustained release of drugs in situations where oral sustained release systems are inadequate. In some cases, drugs cannot be effectively administered orally because the active ingredients are destroyed or altered by the gastrointestinal system. In other cases the drug may be physically or chemically incompatible with the coatings and/or chelating agents used to implement sustained release. In other cases a transdermal delivery system may provide sustained release over a period of days or weeks whereas orally administered drugs may offer sustained performance over only a few hours. A wide variety of active substances can be delivered through transdermal systems so long as the active substance can be provided in a form that can cross the skin barrier.
- transdermal delivery systems are passive, taking the form of a patch that is adhesively attached to the host.
- the patch includes a quantity of the active substance, along with a suitable carrier if need be, absorbed in a sponge or similar system.
- the active ingredient diffuses into the host through the skin at a rate determined by the concentration of the active substance and the diffusivity of the active substance.
- Active transdermal delivery systems have been developed to help regulate the delivery rate by providing mechanisms to improve drug delivery over time by “pumping” the active ingredient.
- One such system is described in U.S. Pat. No.
- 5,370,635 entitled “DEVICE FOR DELIVERING A MEDICAMENT” which describes a system for delivering a medicament and dispensing it to an organism for a relatively long period of time, for example at least a few days.
- the device can be adapted for positioning on the surface of the skin of a human or possibly an animal body in order to apply a medicament thereto from the outer side thereof.
- transdermal systems circumvent the disadvantages of the adsorption through the gastrointestinal tract, but they do not optimize or tailor the dosing regiment to offset peak symptoms.
- constant transdermal delivery of a drug can lead to severe side effects, including debilitating sleep disorders and ever increasing tolerance.
- the present invention involves synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and pre programmable transdermal or other drug administration system.
- this invention describes a method to maximize the efficiency of compound administration, decrease negative side effects and increase the efficacy of pharmacological therapy by synchronizing and tailoring the administration of certain compounds to match these circadian rhythms.
- the present invention describes methods for treating diseases, addictions and disorders in humans. These methods involve synchronizing and tailoring the administration of compounds with the body's natural circadian rhythms to counteract symptoms when they are likely to be at their worst by using an automated and pre programmable transdermal drug administration system.
- FIG. 1 shows an exemplary device useful for implementing the present invention
- FIG. 2A and FIG. 2B illustrate comparative drug release profiles demonstrating operation of the present invention
- FIG. 3 is a schematic illustration of a drug delivery device in accordance with the present invention.
- FIG. 4 is a schematic illustration of an alternative drug delivery device in accordance with the present invention.
- FIG. 5 shows an exemplary administration profile for a stimulant delivery system
- FIG. 6 shows an exemplary administration profile for a nicotine delivery system
- FIG. 7 shows an exemplary administration profile for a nitroglycerine delivery system tailored to treat variant angina attacks.
- FIG. 8 illustrates an exemplary administration profile for a nitroglycerine delivery system tailored to treat stress-induced angina attack.
- the present invention involves precisely timing the administration of drugs so that they reach peak levels in synchronization with times when symptoms are likely to be at their worst, or times at which the drugs are believed to be more effective in the body and/or better tolerated by the patient.
- the present invention is described in terms of a particular example drug delivery system that provides automated and precise control over dosing, with single-dose capability, (once while people sleep) or capability to administer separate and varying-sized doses many times throughout a multiple day period.
- the particular implementation is consistent with a commercial development of a miniaturized, automated and programmable non-invasive drug delivery system called the ChronoDoseTM system being developed by the assignee of the present invention.
- the system enables controlling of the amount of drug exposed to the skin in a controlled time dependent way according to a programmed administration schedule that implements a desired dosage profile.
- the present invention enables one to precisely control and vary the time of drug release and the amount of each dose, pursuant to an easily set pre-programmed dosage profile.
- Chrono-Pharmacology To illustrate the importance of Chrono-Pharmacology consider the following facts:
- substances with proven or suspected chrono-pharmacological efficiency are integrated into a miniaturized, automated, programmable watch-like device, such as device 100 shown in FIG. 1 .
- the delivery system 100 shown in FIG. 1 can be used for a variety of active compositions, and is small, fully automated and programmable.
- This system consists of a re-usable wristwatch-like device 101 to control the time and dosage of drug delivery; and a small, disposable, ‘reservoir’ 103 , which is about the size of a quarter or 1 ⁇ 2 dollar coin in a particular example, that the user can simply pop-in to place on the watch-like platform.
- This reservoir patch lasts, for example, up to 72 hours, depending on the application. Shorter and longer reservoir lifetimes are contemplated.
- the device is readily adapted to be worn on the forearm, ankle, or other convenient body location.
- the replaceable reservoir can include a description of an administration schedule that can be used to manually or automatically program device 100 with an administration schedule.
- written schedule can be printed on or affixed to the reservoir 101 or electrically programmed using volatile or non-volatile memory. In this manner a dosing profile can be prescribed and filled by a pharmacy in much the same manner as a conventional drug prescription is handled today.
- An exemplary implementation shown in FIG. 3 comprises a collapsible drug reservoir, an expandable waste reservoir, a micro-pump, electronics for automation, a display, and a highly permeable membrane.
- An exemplary system is described in a PCT application No. PCT/IB2004/002947entitled TRANSDERMAL DRUG DELIVEDRY METHOD AND SYSTEM filed on Sep. 13, 2004 which is incorporated herein by reference.
- the drug reservoir will contain about 3 ml of drug formulation.
- a tiny, miniaturized pump is activated at pre-programmed times and releases a pre-defined amount of drug formulation into the drug chamber, where the formulation comes into contact with highly permeable membrane.
- This membrane rests on the skin, and provides for even diffusion of the drug over the device's drug absorption surface area.
- This membrane works effectively with, and can be coated with, an adhesive.
- the remaining drug formulation is either removed from the membrane area via a waste chamber, containing a hydrophilic substance (hydrogel) or the device is taken off.
- a pressurized drug reservoir is used which minimizes or eliminates need for a micropump.
- Electronics control a valve that allows controlled quantities of the drug to be applied to the drug chamber where the formulation comes into contact with highly permeable membrane.
- transdermal patches for the delivery of pharmaceutical agents. See, for example, U.S. Pat. No. 5,370,635 entitled “DEVICE FOR DELIVERING A MEDICAMENT” the disclosure of which is incorporated herein by reference.
- patches may be constructed using a saturated media, pressurized reservoirs, or unpressurized reservoirs with micropumps for continuous, pulsatile, or on-demand delivery of an active material.
- a pharmaceutically acceptable composition of an active material may be combined with skin penetration enhancers including, but not limited to, oleic acid, amino acids, oleyl alcohol, long chain fatty acids, propylene glycol, polyethylene glycol, isopropanol, ethoxydiglycol, sodium xylene sulfonate, ethanol, N-methylpyrrolidone, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, N-methyl-2-pyrrolidone, and the like, which increase the permeability of the skin to the active material and permit the active material to penetrate through the skin and into the bloodstream.
- skin penetration enhancers including, but not limited to, oleic acid, amino acids, oleyl alcohol, long chain fatty acids, propylene glycol, polyethylene glycol, isopropanol, ethoxydiglycol, sodium xylene sulfonate, ethanol, N-methylpyrrolidone,
- compositions may be combined with one or more agents including, but not limited to, alcohols, moisturizers, humectants, oils, emulsifiers, thickeners, thinners, surface active agents, fragrances, preservatives, antioxidants, vitamins, or minerals.
- Pharmaceutically acceptable compositions may also be combined with a polymeric substance including, but not limited to, ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate, polyvinyl pyrrolidone, and the like, to provide the composition in gel form, which may be dissolved in solvent such as methylene chloride, evaporated to the desired viscosity, and then applied to backing material to provide a patch.
- the backing can be any of the conventional materials such as polyethylene, ethyl-vinyl acetate copolymer, polyurethane and the like.
- Example substances include caffeine and a variety of over-the-counter and prescription stimulants (for treating fatigue, sleep disorders, attention deficit disorders and a variety of other conditions), nicotine (for smoking cessation), nitroglycerin (for treating heart attack and strokes), fentanyl (for treating chronic pain), albutamol (for treating asthma), and selegiline (for treating depression, attention deficit disorder or Parkinson's disease).
- over-the-counter and prescription stimulants for treating fatigue, sleep disorders, attention deficit disorders and a variety of other conditions
- nicotine for smoking cessation
- nitroglycerin for treating heart attack and strokes
- fentanyl for treating chronic pain
- albutamol for treating asthma
- selegiline for treating depression, attention deficit disorder or Parkinson's disease
- Exemplary chrono-pharmacological systems that can make use of the present invention are summarized in Table 1 DISEASES/ CONDITION CHRONOPHARMACOLOGY Morning Adrenaline is lowest in the morning, making waking Lethargy uncomfortable and difficult for many people. This can be treated by administering OTC Stimulant before waking Smoking Nicotine at night creates sleeping disorders Cessation (nightmares), but cravings are the highest after waking up. This can be treated by administering Nicotine before waking up. Angina Angina (variant) attacks occur 30 (thirty) times more often between 2:00 a.m. and 4:00 a.m.
- Depression Selegiline at night can create sleeping disorders (nightmares), but depression symptoms are high immediately upon waking up. This can be treated by administering Selegiline before waking up. Rheumatoid Worst upon awakening. Cortisol and anti-inflammatory Arthritis hormones are very low at night This can be treated by administering medication delivered before waking up. Supplements Vitamins and supplements are best administered in low doses over the course of the day to be most effective.
- the present invention can pre-program the times and amount of each dosage by precisely controlling the amount of drug exposed to the skin during each dosing. This feature is advantageous when a drug is best administered during sleep, e.g., 1 to 2 hours before waking up.
- the present invention precisely counteracts peak disease symptoms and increase patient compliance.
- the present invention represents the first true non-invasive chrono-pharmacological drug delivery device. While current transdermal applications are restricted to the dosage profile shown in FIG. 2 a, the automated implementation of the present invention can be programmed for a variety of drug delivery patterns to achieve customized patient dosing regiments for optimal therapy ( FIG. 2 b ). There are many advantages for a controlled transdermal release of an active material such as a drug. As used herein, the term ‘controlled’ or ‘sustained’ release of an active material includes continuous or discontinuous, linear or non-linear release of the active material according to a programmed schedule.
- controlled release Among the advantages of controlled release are the convenience of a single application for the patient, avoidance of peaks and valleys in systemic concentration which can be associated with repeated injections, the potential to reduce the overall dosage of the active material, lower body stress, and the potential to enhance the pharmacological effects of the active material. A lower, sustained dose can also prevent adverse affects that are occasionally observed with infusion therapy. In addition to significantly reducing the cost of care, controlled release drug therapy can free the patient from repeated treatment or hospitalization, thus offering the patient greater flexibility and improving patient compliance. A controlled release formulation of certain drugs also provides an opportunity to use the drug in a manner not previously exploited or considered.
- the present invention is particularly advantageous when (i) known chrono-pharmacological information shows that a drug's effects can optimized when administered in a defined dosage at a predefined time or times, and/or (ii) patient compliance with the dosing regimen is greatly increased due to automation, (doses required at inopportune times, when sleeping, for example).
- a contemplated consumer product is the ArisePatchTM. Most people experience difficulty and discomfort when waking early in the morning. According to a 2002 National Sleep Foundation poll 49% of US adults age 18-29 have trouble waking in the morning and 41% of US adults age 30-64 have trouble waking in the morning. There are 165,000,000 adults in the US alone age 18-64, meaning approximately 74,250,000 US adults age 18-64 have trouble waking in the morning.
- the ArisePatch implementation of the present invention allows individuals, while asleep, to have an over-the-counter (OTC) or prescription stimulant automatically administered during a 1-2 hour pre-wake-up period.
- FIG. 5 illustrates an exemplary stimulant administration profile showing a blood plasma level of ephedrine in nanograms per milliliter on the vertical axis, with time on the horizontal axis. Stimulant concentrations will reach peak levels immediately prior to having to wake. Immediately upon waking up the individual will be alert and feel well rested.
- the ArisePatchTM will eliminate the typical discomfort or difficulty associated with getting up early. This functionality is attractive to employed people getting up for work to ensure punctuality, and just about anyone who wants to offset morning discomfort associated with a late night, jet lag, or sickness.
- Nicotine replacement has been the most frequently used therapy to support smokers in their effort to quit. Smokers report that the craving for a cigarette is greatest immediately upon waking in the morning. The time elapsed between wakening and the first cigarette is the best indicator of addiction. For most smokers this time only a few minutes.
- Nicotine ChronoDoseTM system An exemplary product contemplated by the present invention is called Nicotine ChronoDoseTM system.
- the system can begin to administer nicotine(or nicotine analogs or any other smoking cessation compound including but not limited to Zyban) automatically during a one hour period immediately prior to waking. This will relieve the smoker's peak craving upon waking without causing nightmares and insomnia. We believe that this system clearly provides a superior method for smoking cessation.
- FIG. 6 illustrates an exemplary nicotine administration profile showing a blood plasma level of nicotine in nanograms per milliliter on the vertical axis, with time on the horizontal axis.
- This implementation will reduce nicotine dependency by administering pre-programmed levels of nicotine pursuant to typical smoking patterns. For instance many smokers report that cravings for a cigarette are greatest upon waking up, after lunch, mid afternoon, after dinner and before bedtime.
- This implementation of the present invention will automatically release larger doses of nicotine to offset peak cravings and no nicotine when cravings are typically at a minimum.
- the present invention may be delivered in a pre-programmed manner for each treatment regimen. The only involvement by the user will be the replacement of the ‘reservoir’ every three days, and the replacement of the platform housing as needed.
- This implementation represents a tremendous move forward in nicotine replacement therapy, and is far superior to the old-technology systems that simply release the same amount of nicotine all day and night.
- the present invention one can systematically decrease a smoker's tolerance without increasing dependence (the result of a constant flow) and better wean a smoker off nicotine. This will allow the smoker to better ‘tailor-down’ and decrease the amount of nicotine he needs to quit. Modern smoking cessation is much more than nicotine replacement therapy.
- Programs also include weight control, diet and psychological support. The present invention fits well into these programs, since it addresses the key component of being able to quit smoking by efficiently countering the withdrawal symptoms while doing away with the negative side effects of current nicotine replacement therapy systems, namely sleep disturbance.
- Cold and flu symptoms are worst from midnight until the early morning because the concentration of cortisol is lowest at that time.
- Current night time cold and flu medication end up losing efficacy by early morning when cold and flu symptoms are highest. Therefore people suffering from a cold or flu are often unpleasantly awoken by an increase in symptoms, cutting sleep short.
- the present invention will automatically deliver a larger dose of medication and immuno-boosters in the early morning hours to more effectively combat the peak cold and flu symptoms that occur in the morning. Users will experience less severe cold and flu symptoms during the morning hours, will not have their sleep cycle cut short, and will wake up feeling symptom-free.
- This implementation uses prescription or OTC cold medicine alone or optionally in combination with certain transdermally efficacious vitamins and immune system boosters to provide a total solution to cold and flu ailments.
- This is the first cold therapy that combines OTC medicine with supplemental immuno-boosters in a comprehensive and automated manner. Our system will treat the cold symptoms directly and boost the body's immune system to help it heal naturally.
- the Cold and Flu automated transdermal drug delivery system utilizes OTC cold medicine, Vitamin C, Echinacea, and Zinc to provide a total solution to cold and flu ailments, and all while you sleep.
- Cold and flu symptoms are worst in the middle of the night and early morning because the hormone cortisol, a key inflammation fighter, is missing at that time.
- Cold and flu symptoms are worst from midnight until the early morning because the concentration of cortisol is lowest at that time.
- Current night time cold and flu medication end up losing efficacy by early morning when cold and flu symptoms are highest. Therefore people suffering from a cold or flu are often unconsciously awoken by an increase in symptoms, cutting sleep short
- the Cold and Flu automated transdermal drug delivery system utilizes our proprietary technology to automatically deliver a larger dose of medication and immuno-boosters in the early morning hours to more effectively combat the peak cold and flu symptoms that occur in the morning. Users will experience less severe cold and flu symptoms during the morning hours, will not have their sleep cycle cut short, and will wake up feeling symptom-free.
- Cold and flu symptoms are worst in the middle of the night and early morning because the hormone cortisol, a key inflammation fighter, is missing at that time.
- Our system utilizes its core competitive advantage by pre-programming our System to release more medicaments precisely at that time to offset these peak symptoms.
- Current cold and flu medications end up losing efficacy by early morning when cold symptoms peak, so the user either has sleep cut short due to the onset of these symptoms, or wakes up out of slumber feeling sick with peak symptoms.
- Our system will ensure that a while a person is actually sleeping, a sufficient dose of cold and flu medicine is freshly delivered to offset these peak morning symptoms.
- a series of weight loss vitamins and supplements is administered in small distinct doses many times over a multiple day period. Vitamins and supplements are absorbed by the body in small dosages. Contrary to popular belief, once-a-day products are not maximally effective because excess dosages are excreted unused.
- This implementation of the present invention precisely controls the timing and dosage of small but distinct amounts of vitamins and supplements during a 24 hour period to ensure that vitamins and supplements are constantly bio-available for optimal absorption and cellular function. Greater doses are automatically released prior to mealtimes to counter appetite cravings, resulting in a much more effective diet program.
- nitroglycerine loses its effectiveness and requires higher and higher dosages when administered constantly. Our bodies become tolerant to it. Current systems cannot stop or decrease the release of nitroglycerine when disease symptoms are lowest. Thus, these current ‘dumb’ patches cannot offset the critical angina phase by releasing more of the drug, nor can they shut down or stop nitroglycerine administration when the body doesn't need it. It is a ‘one dose fits all’ type of scenario once each “dumb” patch is applied to the patient.
- the method in accordance with the present invention utilizes an automated transdermal system in order to transdermally administer more nitroglycerine during the critical angina phase to ensure adequate offset of these symptoms and less nitroglycerine when it is not needed so that no tolerance builds up.
- Our method utilizes a ‘smart’ patch medicine system at this time to offset these peak critical phases in the disease cycle arising due to the human body's circadian rhythm.
- the preprogrammable automated transdermal system is worn around the wrist like a watch (or the forearm arm or ankle) and releases nitroglycerine in optimal dosages at times that are optimally synchronized. This is pursuant to a pre-programmed and tailored dosage profile.
- Current nitroglycerin patches only have the capability to release a constant dose of nitroglycerin over a period of time.
- Current nitroglycerin patches simply cannot alter or vary dosages to increase dosages at different times of the day, and decrease dosages at other times of the day.
- the nitroglycerin system in accordance with the present invention has three primary advantages over current nitroglycerin patches.
- the system utilizes its core competitive advantage to automatically and precisely release nitroglycerin in peak amounts to offset the peak symptoms of morning attacks occurring during the critical angina phase.
- Current nitroglycerine patches have release rates that stay constant and do not increase to offset critical phases, and do not decrease as symptoms decrease.
- our system solves the tolerance issue by releasing less (or no) nitroglycerin in off-peak hours, and then releasing nitroglycerin at just the right time so that it is present during critical periods, without increasing tolerance.
- our system accomplishes 1 and 2 above automatically, without the need for a patient to wake up to take a drug at this critical phase, which does away with the need for any increased patient compliance.
- nitroglycerin system represents an ideal delivery system for patients who use nitroglycerin regularly for the treatment and/or the prevention of heart attacks and strokes.
- Patient compliance regarding the timing and dose of heart attack medication is crucial.
- Patient non-compliance with physician's instructions for this is often a cause of re-hospitalization, according to the US Department of Health and Human Services.
- the system solves this problem, and will decrease the need for re-hospitalization by dramatically increasing patient compliance.
- This system can be either an ‘wear each night and remove in the morning’ system, whereby it only releases nitroglycerine automatically to offset the critical angina phase in the morning, or a ‘total solution’ system, that is worn for a period of 24 hours to several days, and that administers nitroglycerine in tailored amounts and at tailored times as synchronized with the body's circadian rhythm (and conveniently taken off while showering or swimming).
- the system is an innovative new drug therapy for angina. With its superior advantage of optimized and automated time and dose administration synchronized with our circadian rhythms, the system in accordance with the present invention ensures that nitroglycerin will circulate in the bloodstream exactly when the patient needs it, and without any build up tolerance. For these reasons, our system is superior to current steady release nicotine patches. Our system's increased advantages are extremely relevant for those patients with moderate to severe angina.
- FIG. 7 shows an exemplary administration profile for a nitroglycerine delivery system tailored to treat variant angina attacks or angina pectoris.
- This type of angina attack has a peak frequency in many patients between the hours of 2:00 and 4:00 AM. This is a particularly difficult time to wake up to take a drug such as nitroglycerine.
- an administration profile substantially like that shown in FIG. 7 is automatically administered.
- the vertical axis indicates blood plasma level in nanograms per milliliter
- the horizontal axis indicates time from 10:00 PM through the night to 8:00 AM.
- FIG. 8 illustrates an exemplary administration profile for a nitroglycerine delivery system tailored to treat stress-induced angina attack.
- the vertical axis indicates blood plasma level in nanograms per milliliter, and the horizontal axis indicates time from 12:00 AM through the day until about 4:00 PM.
- the administration profile shown in FIG. 8 provides a high blood plasma concentration throughout the waking hours of a day when stress is likely occur.
- the automated transdermal asthma system automatically administers a morning dose of albuterol, tolobuterol, salmeterol, beta 2 agonist or any other antiarrhythmic drug (an ‘Asthma drug’) to combat the peak symptom of morning asthma attacks known as the ‘morning dip’.
- Asthma attacks occur 100 (one hundred) times more often between the hours 4 A.M. and 6 A.M., when most people are asleep. This is due to the early morning deterioration of respiratory function known as ‘morning dip’, which is the time of day that respiratory function is at its lowest. These early morning asthma attacks cause great distress to sufferers and care providers.
- the morning dip represents the dip in respiratory function at this time when asthma attacks are 100 times more likely to occur.
- Our system effectively combats the morning dip by releasing more Asthma drug at this time to offset this peak morning symptom .
- our ‘smart’ patch varies the level of drug in the bloodstream so that drug concentrations are highest when respiratory function is at its lowest.
- the Asthma system has two primary advantages over current patches.
- First, the system of the present invention utilizes its core competitive advantage to automatically and precisely release albuterol or other asthma drugs in peak amounts to offset the peak symptoms associated with the morning dip.
- Current patches have release rates that stay constant and do not increase to offset this peak critical phases, and do not decrease as symptoms decrease.
- Second, our system accomplishes 1 and 2 above automatically, without the need for a patient to wake up to take a drug at this critical phase, which does away with the need for any increased patient compliance.
- the automated transdermal system for Asthma is worn around the wrist like a watch (or the forearm arm or ankle) and releases albuterol or other Asthma drugs in optimal dosages at times that are optimally synchronized, especially to offset the morning dip, pursuant to a pre-programmed and tailored dosage profile.
- Current Asthma patches only have the capability to release a constant dose over a period of time.
- Current Asthma patches simply cannot alter or vary dosages to increase dosages at different times of the day, and decrease dosages at other times of the day.
- the system is an innovative new drug therapy for asthma. With its superior advantage of optimized and automated time and dose administration synchronized with our circadian rhythms, our system ensures that albuterol or another asthma drug will circulate in increased amounts in the bloodstream exactly when the patient needs it. For these reasons, our system is superior to current steady release patches. Our system's increased advantages are extremely relevant for those patients with moderate to severe asthma.
- the clondine automated transdermal system utilizes clondine, (or another hypertension drug) an effective drug that combats high blood pressure.
- the clondine automated transdermal drug delivery system has an automated morning release of Clondine to combat the peak symptom of morning heart attacks.
- Blood pressure differs at different times of the day. Blood pressure surges upon waking, and is lower by 20 to 30 per cent while sleeping.
- Our preprogrammed automatic transdermal system utilizes its core competitive advantage by releasing clondine in a tailored fashion to counter high blood pressure when symptoms are highest, while releasing less clondine when symptoms are less severe.
- the automated transdermal system for hypertension has two primary advantages over current patches.
- First, our system utilizes its core competitive advantage to automatically and precisely release clondine or other hypertension drugs in peak amounts to offset the peak symptoms associated with the dangerous morning symptoms.
- Current hypertension patches have release rates that stay constant and do not increase to offset this peak critical phases, and do not decrease as symptoms decrease.
- Second, our system accomplishes 1 and 2 above automatically, without the need for a patient to wake up to take a drug at this critical phase, which does away with the need for any increased patient compliance.
- the selegiline automated transdermal system utilizes selegiline, an effective MAO inhibitor for the treatment of depression, Alzheimer's and Attention Deficit Disorder.
- the selegiline automated transdermal drug delivery system gives an automated morning release of selegiline to combat the peak symptom of morning depression without the side effect of sleep disturbances.
- the system in accordance with the present invention is applied before bed. It does not release the drug until an hour or 2 before morning, so symptom of morning depression would be corrected by our system without subjecting the patient to sleep disturbances.
- the present invention is particularly useful in applications in which it is necessary and/or desirable to start the administration of a drug, stop the administration of a drug, and/or increase/decrease the dosage of a drug at a time when it is inconvenient or impossible for a patient to initiate the necessary actions.
- This is particularly useful for a wide variety of drug administration applications that benefit when administration is started, stopped, or changed while a person is sleeping.
- chronotherapy knowledge increases, it is contemplated that a wide variety of applications will be discovered in which benefit is realized by starting, stopping and/or changing the drug administration while a patient sleeps.
- treatment is continued as needed to provide superior symptomatic relief, prevent exacerbation of symptoms, and/or prevent and/or delay progression of the disease state or condition in the patient, or until it is no longer well tolerated by the patient, or until a physician terminates treatment.
- a physician may monitor one or more symptoms and/or serum levels of active material and/or metabolic by-product(s) in a patient being treated according to this invention and, upon observing attenuation of one or more symptoms for a period of time, conclude that the patient can sustain the positive effects of the above-described treatment without further administration for a period of time. When necessary, the patient may then return at a later point in time for additional treatment as needed.
- day means a 24-hour period.
- ‘for at least three consecutive days’ means for at least a 72-hour period.
- a physician may monitor one or more symptoms and/or serum levels in the patient and, upon observing an improvement in one or more of the parameters for a period of time, conclude that the patient can sustain the positive effects of the treatment without further administration of the active material for a period of time.
- an active material for therapeutic treatment including prophylactic treatment
- the active material is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
- a pharmaceutical composition comprising an active material in association with a pharmaceutically acceptable diluting substance or carrier, wherein the active material is present in an amount for effective treating or preventing a particular condition. While individual needs may vary, determination of optimal ranges for effective amounts of an active ingredient (alone or in combination with other drugs) within the ranges disclosed herein is within the expertise of those skilled in the art. Accordingly, ‘effective amounts’ of each component for purposes herein are determined by such considerations and are amounts that improve one or more active ingredient functions and/or ameliorate on or more deleterious conditions in patients and/or improve the quality of life in patients.
- kits for treating a particular symptom, condition and/or disease and/or improving a particular biological function comprising one or more containers comprising one or more active compositions in accordance with this invention.
- Such kits can also include additional drugs or therapeutics for co-use with the active composition for treatment or prevention of a particular symptom, condition and/or disease and/or improving a particular biological function .
- the active composition and the drug can be formulated in admixture in one container, or can be contained in separate containers for simultaneous or separate administration.
- the kit can further comprise a device(s) for administering the compounds and/or compositions, such as device 100 shown in FIG. 1 , and written instructions in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflect approval by the agency of manufacture, use or sale for human administration.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/032672 WO2006031856A2 (fr) | 2004-09-13 | 2005-09-13 | Administration de medicament transdermique biosynchrone |
EP05796698.8A EP1802258A4 (fr) | 2004-09-13 | 2005-09-13 | Administration de medicament transdermique biosynchrone |
AU2005284908A AU2005284908B2 (en) | 2004-09-13 | 2005-09-13 | Biosynchronous transdermal drug delivery |
CA2580329A CA2580329C (fr) | 2004-09-13 | 2005-09-13 | Administration de medicament transdermique biosynchrone |
US11/162,517 US20070191815A1 (en) | 2004-09-13 | 2005-09-13 | Biosynchronous transdermal drug delivery |
JP2007531458A JP5254616B2 (ja) | 2004-09-13 | 2005-09-13 | 生物学的同調性(biosynchronous)経皮的薬物送達 |
US11/162,525 US7780981B2 (en) | 2004-09-13 | 2005-09-13 | Biosynchronous transdermal drug delivery |
US12/835,693 US20100280432A1 (en) | 2004-09-13 | 2010-07-13 | Biosynchronous transdermal drug delivery |
US14/162,156 US20140200525A1 (en) | 2003-10-27 | 2014-01-23 | Biosynchronous transdermal drug delivery |
US14/746,689 US9555226B2 (en) | 2003-10-27 | 2015-06-22 | Transdermal drug delivery method and system |
US14/746,704 US9555227B2 (en) | 2004-09-13 | 2015-06-22 | Biosynchronous transdermal drug delivery |
US15/385,638 US10716764B2 (en) | 2003-10-27 | 2016-12-20 | Transdermal drug delivery method and system |
US15/385,665 US20170100573A1 (en) | 2004-09-13 | 2016-12-20 | Biosynchronous transdermal drug delivery |
US16/799,578 US11471424B2 (en) | 2004-09-13 | 2020-02-24 | Biosynchronous transdermal drug delivery |
US16/933,836 US20210169822A1 (en) | 2003-10-27 | 2020-07-20 | Transdermal drug delivery method and system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60941804P | 2004-09-13 | 2004-09-13 | |
US11/162,517 US20070191815A1 (en) | 2004-09-13 | 2005-09-13 | Biosynchronous transdermal drug delivery |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/892,006 Continuation US8673346B2 (en) | 2003-10-27 | 2013-05-10 | Transdermal drug delivery method and system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/162,156 Continuation US20140200525A1 (en) | 2003-10-27 | 2014-01-23 | Biosynchronous transdermal drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070191815A1 true US20070191815A1 (en) | 2007-08-16 |
Family
ID=38024536
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/162,517 Abandoned US20070191815A1 (en) | 2003-10-27 | 2005-09-13 | Biosynchronous transdermal drug delivery |
US11/162,525 Active 2027-10-31 US7780981B2 (en) | 2004-09-13 | 2005-09-13 | Biosynchronous transdermal drug delivery |
US12/835,693 Abandoned US20100280432A1 (en) | 2004-09-13 | 2010-07-13 | Biosynchronous transdermal drug delivery |
US14/162,156 Abandoned US20140200525A1 (en) | 2003-10-27 | 2014-01-23 | Biosynchronous transdermal drug delivery |
US14/746,689 Active US9555226B2 (en) | 2003-10-27 | 2015-06-22 | Transdermal drug delivery method and system |
US14/746,704 Active US9555227B2 (en) | 2004-09-13 | 2015-06-22 | Biosynchronous transdermal drug delivery |
US15/385,638 Active 2024-10-20 US10716764B2 (en) | 2003-10-27 | 2016-12-20 | Transdermal drug delivery method and system |
US15/385,665 Abandoned US20170100573A1 (en) | 2004-09-13 | 2016-12-20 | Biosynchronous transdermal drug delivery |
US16/799,578 Active US11471424B2 (en) | 2004-09-13 | 2020-02-24 | Biosynchronous transdermal drug delivery |
US16/933,836 Abandoned US20210169822A1 (en) | 2003-10-27 | 2020-07-20 | Transdermal drug delivery method and system |
Family Applications After (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/162,525 Active 2027-10-31 US7780981B2 (en) | 2004-09-13 | 2005-09-13 | Biosynchronous transdermal drug delivery |
US12/835,693 Abandoned US20100280432A1 (en) | 2004-09-13 | 2010-07-13 | Biosynchronous transdermal drug delivery |
US14/162,156 Abandoned US20140200525A1 (en) | 2003-10-27 | 2014-01-23 | Biosynchronous transdermal drug delivery |
US14/746,689 Active US9555226B2 (en) | 2003-10-27 | 2015-06-22 | Transdermal drug delivery method and system |
US14/746,704 Active US9555227B2 (en) | 2004-09-13 | 2015-06-22 | Biosynchronous transdermal drug delivery |
US15/385,638 Active 2024-10-20 US10716764B2 (en) | 2003-10-27 | 2016-12-20 | Transdermal drug delivery method and system |
US15/385,665 Abandoned US20170100573A1 (en) | 2004-09-13 | 2016-12-20 | Biosynchronous transdermal drug delivery |
US16/799,578 Active US11471424B2 (en) | 2004-09-13 | 2020-02-24 | Biosynchronous transdermal drug delivery |
US16/933,836 Abandoned US20210169822A1 (en) | 2003-10-27 | 2020-07-20 | Transdermal drug delivery method and system |
Country Status (6)
Country | Link |
---|---|
US (10) | US20070191815A1 (fr) |
EP (1) | EP1802258A4 (fr) |
JP (1) | JP5254616B2 (fr) |
AU (1) | AU2005284908B2 (fr) |
CA (1) | CA2580329C (fr) |
WO (1) | WO2006031856A2 (fr) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060062838A1 (en) * | 2004-09-13 | 2006-03-23 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
US20080220092A1 (en) * | 2004-09-13 | 2008-09-11 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20100169260A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
USRE46217E1 (en) | 2005-05-24 | 2016-11-29 | Chrono Therapeutics Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
US9724483B2 (en) | 2008-12-30 | 2017-08-08 | Gearbox, Llc | Method for administering an inhalable compound |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100260669A1 (en) * | 2004-05-13 | 2010-10-14 | Anthony Joonkyoo Yun | Treatment of Seasonal Conditions Through Modulation of the Autonomic Nervous System |
US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
CN101528698A (zh) * | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
WO2008015607A1 (fr) * | 2006-08-02 | 2008-02-07 | Koninklijke Philips Electronics N.V. | Dispositif destiné à assister une prise de décision concernant un traitement médical et/ou à surveiller l'état d'un patient |
WO2008032238A2 (fr) * | 2006-09-13 | 2008-03-20 | Koninklijke Philips Electronics N. V. | Dispositif de régulation automatique d'une dose de mélatonine et/ou de l'administration de mélatonine |
US20080107719A1 (en) * | 2006-11-08 | 2008-05-08 | Sukhon Likitlersuang | Transdermal drug delivery system |
US20080152709A1 (en) * | 2006-12-22 | 2008-06-26 | Drugtech Corporation | Clonidine composition and method of use |
US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
US7715679B2 (en) | 2007-05-07 | 2010-05-11 | Adc Telecommunications, Inc. | Fiber optic enclosure with external cable spool |
CA2687979C (fr) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Formulations d'administration prolongee de composes de risperidone |
JP2010535237A (ja) * | 2007-07-31 | 2010-11-18 | ターガセプト・インコーポレイテッド | (2s)−(4e)−n−メチル−5−(3−(5−イソプロポキシピリジン)イル)−4−ペンテン−2−アミンの経皮投与 |
WO2009026139A1 (fr) * | 2007-08-17 | 2009-02-26 | Isis Biopolymer Llc | Système d'administration de médicament iontophorétique |
US20100121307A1 (en) * | 2007-08-24 | 2010-05-13 | Microfabrica Inc. | Microneedles, Microneedle Arrays, Methods for Making, and Transdermal and/or Intradermal Applications |
JP2011517578A (ja) * | 2007-12-10 | 2011-06-16 | アイシス バイオポリマー,インク. | イオントフォレシス薬剤投与装置及びソフトウェアアプリケーション |
DK2141620T3 (en) * | 2008-07-01 | 2019-02-18 | Hoffmann La Roche | Insulin pump and method for controlling one of the insulin pump's user interface |
EP2419085A4 (fr) * | 2009-04-14 | 2013-04-24 | Univ California | Dispositifs améliorés pour médicaments à usage oral et formulations médicamenteuses |
US20110092881A1 (en) * | 2009-05-08 | 2011-04-21 | Isis Biopolymer Inc. | Iontophoretic device with contact sensor |
WO2010129928A1 (fr) * | 2009-05-08 | 2010-11-11 | Isis Biopolymer Llc | Dispositif iontophorétique avec contre-électrode améliorée |
US8758323B2 (en) | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
WO2011146009A1 (fr) | 2010-05-20 | 2011-11-24 | Targacept Inc. | Nouveau procédé pour la préparation d'amines oléfiniques à substitution aryle |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
DE102010030502A1 (de) | 2010-06-24 | 2011-12-29 | HSG-IMIT-Institut für Mikro- und Informationstechnologie | Quellstoffaktor und Fördereinrichtung, insbesonder für eine medizinische Wirksubstanz |
US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
ES2741348T3 (es) * | 2012-03-13 | 2020-02-10 | Becton Dickinson France | Dispositivo de inyección que tiene una porción de administración de fármaco miniaturizada |
US9539201B2 (en) | 2012-04-20 | 2017-01-10 | KAT Transdermals LLC | Selegiline transdermal system |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US20140207047A1 (en) * | 2013-01-22 | 2014-07-24 | Chrono Therapeutics, Inc. | Transdermal drug delivery system and method |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9492608B2 (en) | 2013-03-15 | 2016-11-15 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
CA2924154A1 (fr) * | 2013-09-11 | 2015-03-19 | Incube Labs, Llc | Systeme et methode de regulation de l'administration iontophoretique d'agents therapeutiques reposant sur l'inhalation des utilisateurs |
FR3015300B1 (fr) * | 2013-12-20 | 2018-03-02 | L'oreal | Dispositif d'iontophorese a reservoir |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
US10004887B2 (en) | 2015-02-18 | 2018-06-26 | Alma Therapeutics Ltd. | Transdermal delivery assembly |
US11147955B2 (en) | 2015-02-18 | 2021-10-19 | Alma Therapeutics Ltd. | Regulator device for drug patch |
WO2016168847A1 (fr) * | 2015-04-17 | 2016-10-20 | Georgia Tech Research Corporation | Dispositifs d'administration de médicament avec des micro-aiguilles séparables |
WO2017019526A2 (fr) | 2015-07-24 | 2017-02-02 | Kimberly-Clark Worldwide, Inc. | Procédés pour l'administration améliorée de principes actifs à des tumeurs |
WO2017079760A1 (fr) * | 2015-11-06 | 2017-05-11 | Bkr Ip Holdco Llc | Procédé de contrôle de la glycémie chez des personnes diabétiques |
EP3386563B1 (fr) | 2015-12-11 | 2019-10-16 | SeraIP AG | Dispositif d'interface de fluide pour distribuer un fluide et/ou retirer un fluide d'un patient |
EP3416718A4 (fr) | 2016-02-18 | 2020-03-11 | Alma Therapeuthics Ltd. | Dispositif de régulation pour patch médicamenteux |
EP3321899A1 (fr) * | 2016-11-10 | 2018-05-16 | Therasolve NV | Unité de communication électronique pour un patch adhésif |
WO2019241711A1 (fr) * | 2018-06-14 | 2019-12-19 | Sabiev Anton | Timbre d'iontophorèse sans fil et dispositif de commande |
US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
WO2023276090A1 (fr) * | 2021-06-30 | 2023-01-05 | シンクランド株式会社 | Appareil d'administration transdermique et système d'administration transdermique |
WO2023108207A1 (fr) * | 2021-12-17 | 2023-06-22 | Cosmoaesthetics Pty Ltd | Applicateur transdermique de médicament à porter sur soi |
US20240153607A1 (en) * | 2022-11-08 | 2024-05-09 | Arcascope Inc. | System for Determining Treatment Timing and Methods of Treatment Timed Based on Biological Process Indicators |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4545990A (en) * | 1982-11-22 | 1985-10-08 | L'oreal | Anti-acne composition |
US4708716A (en) * | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US4917895A (en) * | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
US5242941A (en) * | 1990-12-04 | 1993-09-07 | State Of Oregon | Methods of treating circadian rhythm disorders |
US5273756A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
US5352456A (en) * | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
US5370835A (en) * | 1991-11-21 | 1994-12-06 | Willi Sturtz Maschinenbau GmbH | Method of manufacturing rectangular frames |
US5389679A (en) * | 1992-01-21 | 1995-02-14 | Alliger; Howard | Method of treating small mouth ulcers with lactic acid |
US5405614A (en) * | 1992-04-08 | 1995-04-11 | International Medical Associates, Inc. | Electronic transdermal drug delivery system |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5538503A (en) * | 1993-09-15 | 1996-07-23 | Henley; Julian L. | Programmable apparatus for reducing substance dependency in transdermal drug delivery |
US5616332A (en) * | 1993-07-23 | 1997-04-01 | Herstein; Morris | Cosmetic skin-renewal-stimulating composition with long-term irritation control |
US5785688A (en) * | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
US5879322A (en) * | 1995-03-24 | 1999-03-09 | Alza Corporation | Self-contained transdermal drug delivery device |
US5932240A (en) * | 1992-04-08 | 1999-08-03 | Americare Technology, Inc. | Multidose transdermal drug delivery system |
US5993435A (en) * | 1990-04-30 | 1999-11-30 | Alza Corporation | Device and method of iontophoretic drug delivery |
US6068853A (en) * | 1994-04-13 | 2000-05-30 | Novartis Corporation | Temporally controlled drug delivery systems |
US6090404A (en) * | 1994-01-13 | 2000-07-18 | Lts Lohmann Therapie-Systeme Gmbh | Estradiol penetration enhancers |
US6129702A (en) * | 1996-12-03 | 2000-10-10 | Fraunhofer-Gesellschaft Zur Forderung Angewandten Forschung E.V. | Medicament dosing system |
US6165155A (en) * | 1997-02-07 | 2000-12-26 | Sarcos, Lc | Multipathway electronically-controlled drug delivery system |
US6211296B1 (en) * | 1998-11-05 | 2001-04-03 | The B. F. Goodrich Company | Hydrogels containing substances |
US6214379B1 (en) * | 1998-04-02 | 2001-04-10 | Kv Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
US6374136B1 (en) * | 1997-12-22 | 2002-04-16 | Alza Corporation | Anhydrous drug reservoir for electrolytic transdermal delivery device |
US20020127256A1 (en) * | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
US6539250B1 (en) * | 1999-12-15 | 2003-03-25 | David S. Bettinger | Programmable transdermal therapeutic apparatus |
US20030065294A1 (en) * | 2001-09-28 | 2003-04-03 | Pickup Ray L. | Cutaneous administration system |
US6595956B1 (en) * | 1998-03-23 | 2003-07-22 | Joseph Gross | Drug delivery device |
US6638528B1 (en) * | 2000-01-20 | 2003-10-28 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6723086B2 (en) * | 2001-05-07 | 2004-04-20 | Logiq Wireless Solutions, Inc. | Remote controlled transdermal medication delivery device |
US20040138074A1 (en) * | 2002-05-01 | 2004-07-15 | Nawaz Ahmad | Warming and nonirritating lubricant compositions and method of comparing irritation |
US20050034842A1 (en) * | 2003-08-11 | 2005-02-17 | David Huber | Electroosmotic micropumps with applications to fluid dispensing and field sampling |
US6861066B2 (en) * | 2002-03-11 | 2005-03-01 | Health Plus International Inc. | Method for the delivery of a biologically active agent |
US6887202B2 (en) * | 2000-06-01 | 2005-05-03 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US20050151110A1 (en) * | 2004-01-14 | 2005-07-14 | Minor Barbara H. | Fluoroether refrigerant compositions and uses thereof |
US20050238704A1 (en) * | 2003-10-27 | 2005-10-27 | Werner Zumbrunn | Transdermal drug delivery method and system |
Family Cites Families (346)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2183482A (en) | 1936-12-23 | 1939-12-12 | Schmid Inc Julius | Injector |
US3279653A (en) | 1964-12-17 | 1966-10-18 | Frederick W Pfleger | Escapement controlled dispensing apparatus |
US3845217A (en) | 1972-11-16 | 1974-10-29 | Helsingborg L Ab | Buffered smoking substitute compositions |
GB1528391A (en) | 1976-01-05 | 1978-10-11 | Gildemeister V | Aerosol compositions |
GB2030862A (en) | 1978-04-10 | 1980-04-16 | Smith A | A composition for treating drug addiction such as smoking nicotine-containing products |
US4321387A (en) | 1980-03-21 | 1982-03-23 | Philip Morris, Incorporated | Process for the preparation of optically active nicotine analogs |
US4313439A (en) | 1980-03-24 | 1982-02-02 | Biotek, Inc. | Automated, spring-powered medicament infusion system |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4332945A (en) | 1981-01-29 | 1982-06-01 | Philip Morris, Incorporated | Optically active nicotine analogs and process for their preparation |
US4590278A (en) | 1981-01-29 | 1986-05-20 | Philip Morris Incorporated | Nicotine analogs |
GB8301659D0 (en) | 1983-01-21 | 1983-02-23 | Leo Ab | Smoking substitutes |
US4856188A (en) | 1984-10-12 | 1989-08-15 | Drug Delivery Systems Inc. | Method for making disposable and/or replenishable transdermal drug applicators |
GB2142822B (en) | 1983-06-29 | 1987-02-11 | Alec Stanley Walter Shaw | Nicotine lozenges |
GB8317576D0 (en) | 1983-06-29 | 1983-08-03 | Shaw A S W | Consumer tobacco products |
US5865786A (en) | 1983-08-18 | 1999-02-02 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
BE899037A (fr) | 1984-02-29 | 1984-06-18 | Trenker Ady | Composition a sucer permettant de cesser de fumer |
US4953572A (en) | 1985-04-25 | 1990-09-04 | Rose Jed E | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
EP0225872B1 (fr) | 1985-06-10 | 1992-09-02 | Drug Delivery Systems Inc. | Commande programmable et systeme de montage d'un applicateur de medicaments transdermiques |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4853854A (en) | 1985-12-26 | 1989-08-01 | Health Innovations, Inc. | Human behavior modification which establishes and generates a user adaptive withdrawal schedule |
US4772263A (en) | 1986-02-03 | 1988-09-20 | Regents Of The University Of Minnesota | Spring driven infusion pump |
DE3645036A1 (de) | 1986-11-18 | 1989-01-05 | Forschungsgesellschaft Rauchen | Nikotinhaltiges mittel |
US4917676A (en) | 1986-11-20 | 1990-04-17 | Ciba-Geigy Corporation | User-activated transdermal therapeutic system |
AT391998B (de) | 1987-02-02 | 1990-12-27 | Falko Dr Skrabal | Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen |
US5049387A (en) | 1987-03-09 | 1991-09-17 | Alza Corporation | Inducing skin tolerance to a sensitizing drug |
US5000956A (en) | 1987-03-09 | 1991-03-19 | Alza Corporation | Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug |
US5013293A (en) | 1987-05-28 | 1991-05-07 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US5388571A (en) | 1987-07-17 | 1995-02-14 | Roberts; Josephine A. | Positive-pressure ventilator system with controlled access for nebulizer component servicing |
US5073380A (en) | 1987-07-27 | 1991-12-17 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
EP0311313B1 (fr) | 1987-10-05 | 1995-05-10 | Yamanouchi Pharmaceutical Co. Ltd. | Composés spiro hétérocycliques et leur préparation |
JPH01265021A (ja) | 1987-10-29 | 1989-10-23 | Hercon Lab Corp | 薬理学的活性物質を含有する組成物を動物組織に制御放出および供給するための物品 |
US4885154A (en) | 1988-03-01 | 1989-12-05 | Alza Corporation | Method for reducing sensitization or irritation in transdermal drug delivery and means therefor |
US5472946A (en) | 1988-04-08 | 1995-12-05 | Peck; James V. | Transdermal penetration enhancers |
US5364630A (en) | 1988-06-14 | 1994-11-15 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
US5028428A (en) | 1988-08-09 | 1991-07-02 | Estee Lauder Inc. | Anti-irritant and desensitizing compositions and methods of their use |
US4952928A (en) | 1988-08-29 | 1990-08-28 | B. I. Incorporated | Adaptable electronic monitoring and identification system |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
US5248501A (en) | 1988-11-22 | 1993-09-28 | Parnell Pharmaceuticals | Drug delivery systems containing eriodictyon fluid extract as an excipient, and methods and compositions associated therewith |
IE62662B1 (en) | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
JP2638635B2 (ja) | 1989-01-31 | 1997-08-06 | 積水化学工業株式会社 | 経皮吸収製剤 |
JPH02208813A (ja) | 1989-02-09 | 1990-08-20 | Fuji Photo Film Co Ltd | 薄膜磁気ヘッド |
US4908213A (en) | 1989-02-21 | 1990-03-13 | Schering Corporation | Transdermal delivery of nicotine |
GB2230439A (en) | 1989-04-20 | 1990-10-24 | Alec Stanley Walter Shaw | Nicotine lozenges |
US5262165A (en) | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
US5525351A (en) | 1989-11-07 | 1996-06-11 | Dam; Anders | Nicotine containing stimulant unit |
US5512306A (en) | 1992-06-19 | 1996-04-30 | Pharmica Ab | Smoking substitute |
US5149719A (en) | 1990-04-27 | 1992-09-22 | Minnesota Mining And Manufacturing Company | Composition for transdermal penetration of medicaments |
US5130139A (en) | 1990-07-06 | 1992-07-14 | Alza Corporation | Reduction or prevention of skin irritation by drugs |
US5120545A (en) | 1990-08-03 | 1992-06-09 | Alza Corporation | Reduction or prevention of sensitization to drugs |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5232704A (en) | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
US5221254A (en) | 1991-04-02 | 1993-06-22 | Alza Corporation | Method for reducing sensation in iontophoretic drug delivery |
DK0588917T3 (da) | 1991-05-29 | 2001-02-12 | Abbott Lab | Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
US5273755A (en) | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset |
US5304739A (en) | 1991-12-19 | 1994-04-19 | Klug Reja B | High energy coaxial cable for use in pulsed high energy systems |
GB9200047D0 (en) | 1992-01-03 | 1992-02-26 | Univ Alberta | Nicotine-containing nasal spray |
US6436078B1 (en) | 1994-12-06 | 2002-08-20 | Pal Svedman | Transdermal perfusion of fluids |
IL104365A0 (en) | 1992-01-31 | 1993-05-13 | Gensia Pharma | Method and apparatus for closed loop drug delivery |
CH686816A5 (de) | 1992-02-04 | 1996-07-15 | Asulab Ag | Einrichtung zur Abgabe eines Arzneimittels. |
US5242934A (en) | 1992-03-02 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
US5242935A (en) | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5227391A (en) | 1992-04-10 | 1993-07-13 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5232933A (en) | 1992-05-21 | 1993-08-03 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5310404A (en) | 1992-06-01 | 1994-05-10 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
CA2072040C (fr) | 1992-06-23 | 2002-06-11 | Charles Borg | Methode et dispositif pour faciliter l'acquisition de nouveaux comportement |
US5501697A (en) | 1992-06-23 | 1996-03-26 | Fisher; Gary R. | Treatment device to aid in long-term cessation of smoking |
US5248690A (en) | 1992-07-07 | 1993-09-28 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5252604A (en) | 1992-07-10 | 1993-10-12 | Hoffmann-La Roche Inc. | Compositions of retinoic acids and tocopherol for prevention of dermatitis |
EP0656771A4 (fr) | 1992-08-25 | 1996-07-31 | Cygnus Therapeutic Systems | Dispositif d'apport medicamenteux percutane depose par empreinte. |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
AU5551394A (en) | 1992-11-09 | 1994-06-08 | Pharmetrix Corporation | Combined analgesic delivery methods for pain management |
US5843979A (en) | 1993-02-25 | 1998-12-01 | Bristol-Myers Squibb Company | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
CA2114968A1 (fr) | 1993-02-25 | 1994-08-26 | John Wille | Traitement transdermique par des agents de degranulation des mastocytes pour l'hypersensibilite induite par voie medicamenteuse |
US5516793A (en) | 1993-04-26 | 1996-05-14 | Avon Products, Inc. | Use of ascorbic acid to reduce irritation of topically applied active ingredients |
US5445609A (en) | 1993-05-28 | 1995-08-29 | Alza Corporation | Electrotransport agent delivery device having a disposable component and a removable liner |
US5451407A (en) | 1993-06-21 | 1995-09-19 | Alza Corporation | Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug |
US5549906A (en) | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
US5377258A (en) | 1993-08-30 | 1994-12-27 | National Medical Research Council | Method and apparatus for an automated and interactive behavioral guidance system |
US5533971A (en) | 1993-09-03 | 1996-07-09 | Alza Corporation | Reduction of skin irritation during electrotransport |
AU662877B3 (en) | 1993-10-21 | 1995-09-14 | Amal Hakim Khalil | Nicotine lozenges |
US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
US5393526A (en) | 1994-02-07 | 1995-02-28 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic compositions |
US6121276A (en) | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
US5876368A (en) | 1994-09-30 | 1999-03-02 | Becton Dickinson And Company | Iontophoretic drug delivery device having improved controller |
US5445823A (en) | 1994-10-20 | 1995-08-29 | The Procter & Gamble Company | Dermatological compositions and method of treatment of skin lesions therewith |
US5703100A (en) | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5618557A (en) | 1994-11-22 | 1997-04-08 | E.R. Squibb & Sons, Inc. | Prophylactic treatment of allergic contact dermatitis |
US5686100A (en) | 1994-11-22 | 1997-11-11 | E.R. Squibb & Sons, Inc. | Prophylactic and therapeutic treatment of skin sensitization and irritation |
US5697896A (en) | 1994-12-08 | 1997-12-16 | Alza Corporation | Electrotransport delivery device |
DE4444238A1 (de) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
FR2728793A1 (fr) | 1994-12-28 | 1996-07-05 | Oreal | Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
US5562607A (en) | 1995-01-18 | 1996-10-08 | Alza Corporation | Electrotransport device having reusable controller power saver |
WO1996032142A1 (fr) | 1995-04-12 | 1996-10-17 | Hopp Robert B | Disque transdermique applicable en immunotherapie de contact |
US5601839A (en) | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
US6093419A (en) | 1995-06-07 | 2000-07-25 | Lectec Corporation | Compliance verification method and device in compulsory drug administration |
US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
EP0871627A1 (fr) | 1995-09-22 | 1998-10-21 | Novo Nordisk A/S | Nouveaux composes azacycliques ou azabicycliques a substitution |
AU7083596A (en) | 1995-09-22 | 1997-04-09 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
US5688232A (en) | 1995-09-28 | 1997-11-18 | Becton Dickinson And Company | Iontophoretic drug delivery device having an improved controller |
CA2233197A1 (fr) | 1995-09-28 | 1997-04-03 | Becton, Dickinson And Company | Systeme d'administration iontophoretique de medicaments comprenant un dispositif reutilisable |
JP3969741B2 (ja) | 1995-11-17 | 2007-09-05 | マーク アンド カンパニー インコーポレイテッド | アセチルコリン受容体の修飾因子として役立つ新規置換アリール化合物 |
US8092224B2 (en) | 1995-11-22 | 2012-01-10 | James A. Jorasch | Systems and methods for improved health care compliance |
AU1058797A (en) | 1995-11-22 | 1997-06-11 | Bristol-Myers Squibb Company | Treatment with calcium channel blockers for drug-induced hypersensitivity |
ZA9610374B (en) | 1995-12-11 | 1997-06-23 | Elan Med Tech | Cartridge-based drug delivery device |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5733269A (en) | 1996-03-15 | 1998-03-31 | Fuisz Technologies Ltd. | Method and kit for positioning transdermal delivery system |
AU2340397A (en) | 1996-03-21 | 1997-10-10 | Mayo Foundation For Medical Education And Research | Use of nicotine to treat liver disease |
US6271240B1 (en) | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
ES2206709T3 (es) | 1996-05-13 | 2004-05-16 | Novartis Consumer Health S.A. | Sistema de suministro bucal. |
US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
US5716987A (en) | 1996-06-21 | 1998-02-10 | Bristol-Myers Squibb Company | Prophylactic and therapeutic treatment of skin sensitization and irritation |
GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
US5788671A (en) | 1996-08-14 | 1998-08-04 | Sims Deltec, Inc. | Reusable cassette housings and methods |
US6081734A (en) | 1996-08-16 | 2000-06-27 | Roche Diagnostics Gmbh | Monitoring system for the regular intake of a medicament |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5797867A (en) | 1996-09-27 | 1998-08-25 | Becton Dickinson And Company | Iontophoretic drug delivery system, including method for activating same for attachment to patient |
US5919156A (en) | 1996-09-27 | 1999-07-06 | Becton, Dickinson And Company | Iontophoretic drug delivery system, including unit for dispensing patches |
US6746688B1 (en) | 1996-10-13 | 2004-06-08 | Neuroderm Ltd. | Apparatus for the transdermal treatment of Parkinson's disease |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
DE939862T1 (de) | 1996-11-21 | 2000-04-06 | Lhd Lab Hygiene Dietetique | Mikroventil zum füllen des behälters eines transdermalen medikamentenverabreichungssystems |
US5908301A (en) | 1996-12-05 | 1999-06-01 | Lutz; Raymond | Method and device for modifying behavior |
US8734339B2 (en) | 1996-12-16 | 2014-05-27 | Ip Holdings, Inc. | Electronic skin patch for real time monitoring of cardiac activity and personal health management |
US6019997A (en) | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
US6018679A (en) | 1997-01-29 | 2000-01-25 | Novartis Finance Corp. | Iontophoretic transdermal delivery and control of adverse side-effects |
US6020335A (en) | 1997-02-06 | 2000-02-01 | Pfizer Inc | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents |
US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
IL131713A (en) | 1997-03-11 | 2004-08-31 | Arakis Ltd | Dosage forms comprising separate portions of r- and s-enantiomers |
FR2761072B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique |
US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
WO1998046093A1 (fr) | 1997-04-14 | 1998-10-22 | Robert Lindburg | Dispositif de controle de l'habitude de fumer |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
HUP0002713A3 (en) | 1997-05-30 | 2001-02-28 | Neurosearch As | 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use |
DE69810107T2 (de) | 1997-05-30 | 2003-08-21 | Neurosearch As Ballerup | Azacyclooktan- und heptan-derivate, ihre herstellung und ihre therapeutische verwendung |
NZ500643A (en) | 1997-05-30 | 2001-12-21 | Neurosearch As | Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators |
DE69811070T2 (de) | 1997-05-30 | 2003-10-02 | Neurosearch As Ballerup | 9-azabicyclo(3.3.1)non-2-ene und nonanderivate als liganden der nicotinergen rezeptoren |
DE69831335T3 (de) | 1997-06-06 | 2015-01-15 | Depomed, Inc. | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
FR2765874B1 (fr) | 1997-07-09 | 1999-08-13 | Synthelabo | Derives de 6-pyrrolidin-2-ylpyrindines, leur preparation et leur application en therapeutique |
AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
US6120803A (en) | 1997-08-11 | 2000-09-19 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
US6034079A (en) | 1997-08-11 | 2000-03-07 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
DE19738855C2 (de) | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht |
US5786888A (en) * | 1997-09-16 | 1998-07-28 | Trw Inc. | Pulsed radiation classifier and related method |
US6660295B2 (en) | 1997-09-30 | 2003-12-09 | Alza Corporation | Transdermal drug delivery device package with improved drug stability |
US7011843B2 (en) | 1997-10-01 | 2006-03-14 | Lts Lohmann-Therapie Systeme Ag | Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system |
US5879292A (en) | 1997-10-09 | 1999-03-09 | Edward A. Sternberg | Bandage including data acquisition components |
HU226859B1 (en) | 1997-10-27 | 2009-12-28 | Neurosearch As | Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them |
US6162214A (en) | 1997-10-30 | 2000-12-19 | Eclipse Surgical Technologies, Inc. | Corning device for myocardial revascularization |
EP1034174B1 (fr) | 1997-11-05 | 2003-08-13 | Neurosearch A/S | Derives d'azacyclo-ether et leur utilisation en tant que modulateurs des recepteurs ach nicotiniques |
ES2318233T3 (es) | 1997-11-10 | 2009-05-01 | Strakan International Limited | Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona. |
PT1041975E (pt) | 1997-12-22 | 2003-01-31 | Alza Corp | Membranas de controlo de taxa para dispositivos de fornecimento controlado de drogas |
US6059736A (en) | 1998-02-24 | 2000-05-09 | Tapper; Robert | Sensor controlled analysis and therapeutic delivery system |
CA2231968A1 (fr) | 1998-03-11 | 1999-09-11 | Smoke-Stop, A Partnership Consisting Of Art Slutsky | Methode de production d'un medicament a base de nicotine |
US6057446A (en) | 1998-04-02 | 2000-05-02 | Crooks; Peter Anthony | Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds |
US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
EP0955301A3 (fr) | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux |
US6211194B1 (en) | 1998-04-30 | 2001-04-03 | Duke University | Solution containing nicotine |
US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
US5967789A (en) | 1998-07-30 | 1999-10-19 | Smoke Stoppers International, Inc. | Method and system for stopping or modifying undesirable health-related behavior habits or maintaining desirable health-related behavior habits |
US6365182B1 (en) | 1998-08-12 | 2002-04-02 | Cima Labs Inc. | Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet |
US6368625B1 (en) | 1998-08-12 | 2002-04-09 | Cima Labs Inc. | Orally disintegrable tablet forming a viscous slurry |
ES2226427T3 (es) | 1998-08-25 | 2005-03-16 | Ortho-Mcneil Pharmaceutical, Inc. | Esteres y tioeteres de piridillo como agonistas de receptor de acetilcolina nicotinico y aplicacion terapeutica. |
US6165165A (en) * | 1998-10-02 | 2000-12-26 | Genx International, Inc. | Embryo-implanting catheter assembly and method for making the same |
US6262124B1 (en) | 1998-10-22 | 2001-07-17 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
DE69914935T2 (de) | 1998-11-27 | 2009-10-01 | Neurosearch A/S | 8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate |
FR2786770B1 (fr) | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
FR2786769B1 (fr) | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
DE69930552T2 (de) | 1998-12-16 | 2006-11-30 | University Of South Florida, Tampa | Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen |
KR100383252B1 (ko) | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
EP1147112B1 (fr) | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Derives diazabicycliques utiles en tant que ligands du recepteur nicotinique de l'acetylcholine |
US6583160B2 (en) | 1999-04-14 | 2003-06-24 | Steve Smith | Nicotine therapy method and oral carrier for assuaging tobacco-addiction |
US6454708B1 (en) | 1999-04-15 | 2002-09-24 | Nexan Limited | Portable remote patient telemonitoring system using a memory card or smart card |
US6416471B1 (en) | 1999-04-15 | 2002-07-09 | Nexan Limited | Portable remote patient telemonitoring system |
CN1348449A (zh) | 1999-04-26 | 2002-05-08 | 神经研究公司 | 杂芳基二氮杂环烷烃及其制备方法和应用 |
JP2002543208A (ja) | 1999-04-29 | 2002-12-17 | ザ ダウ ケミカル カンパニー | ビス(n、n−ジヒドロカルビルアミノ)置換シクロペンタジエン及びそれらの金属錯体 |
US6689380B1 (en) | 1999-05-17 | 2004-02-10 | Kevin S. Marchitto | Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy |
DE19925613A1 (de) * | 1999-06-04 | 2000-12-07 | Lohmann Therapie Syst Lts | Verbundlaminat und Verfahren zu seiner Herstellung |
EP1187653B1 (fr) | 1999-06-04 | 2010-03-31 | Georgia Tech Research Corporation | Dispositifs permettant d'ameliorer la penetration d'une microaiguille a travers des barrieres tissulaires |
US6567785B2 (en) | 1999-06-19 | 2003-05-20 | John Richard Clendenon | Electronic behavior modification reminder system and method |
DE19958554C2 (de) | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung |
US20040229908A1 (en) | 1999-07-13 | 2004-11-18 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias |
US8256433B2 (en) | 1999-07-16 | 2012-09-04 | Aradigm Corporation | Systems and methods for effecting cessation of tobacco use |
US20080138398A1 (en) | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
US6799576B2 (en) | 1999-07-16 | 2004-10-05 | Aradigm Corporation | System for effecting smoking cessation |
CA2378913C (fr) | 1999-07-16 | 2010-02-23 | Aradigm Corporation | Systeme permettant d'arreter de fumer |
US20080138294A1 (en) | 1999-07-16 | 2008-06-12 | Igor Gonda | Systems and methods for effecting cessation of tobacco use |
US20080138399A1 (en) | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
EP1210064B1 (fr) | 1999-08-18 | 2005-03-09 | Microchips, Inc. | Dispositifs de liberation chimique a microplaquette a activation thermique |
US7376700B1 (en) | 1999-08-23 | 2008-05-20 | Wellcoaches Corporation | Personal coaching system for clients with ongoing concerns such as weight loss |
FR2798065B1 (fr) | 1999-09-02 | 2003-09-05 | Assist Publ Hopitaux De Paris | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
KR20010036685A (ko) | 1999-10-11 | 2001-05-07 | 김윤 | 펜타닐을 함유하는 매트릭스형 경피투여제 |
SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
WO2001037814A1 (fr) | 1999-11-23 | 2001-05-31 | Robert Gordon University | Comprimes bicouches a administration buccale comprenant de la nicotine |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
JP2001261652A (ja) | 2000-03-21 | 2001-09-26 | Suntory Ltd | 二置換イミノヘテロサイクリック化合物 |
US6437004B1 (en) | 2000-04-06 | 2002-08-20 | Nicholas V. Perricone | Treatment of skin damage using olive oil polyphenols |
US6489025B2 (en) | 2000-04-12 | 2002-12-03 | Showa Denko K.K. | Fine carbon fiber, method for producing the same and electrically conducting material comprising the fine carbon fiber |
US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
WO2001089571A2 (fr) | 2000-05-19 | 2001-11-29 | Sabinsa Corporation | Methode permettant d'augmenter la biodisponibilite de nutriments et preparations pharmaceutiques renfermant de la tetrahydropiperine et des analogues et derives de tetrahydropiperine |
EP2363061A1 (fr) | 2000-06-16 | 2011-09-07 | BodyMedia, Inc. | Systeme de surveillance et de gestion du poids du corps et d'autres etats physiologiques comprenant un programme interactif et personnalise et des capacites d'intervention et capacite de rapport |
WO2002002081A1 (fr) | 2000-07-05 | 2002-01-10 | Capricorn Pharma, Inc. | Composition semi-solide a fusion rapide, leurs procedes de production et leurs procedes d'utilisation |
US6589229B1 (en) | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
JP2002092180A (ja) | 2000-09-19 | 2002-03-29 | Hiroko Takahashi | 禁煙支援システム |
WO2002030392A2 (fr) | 2000-10-12 | 2002-04-18 | Beecham Pharmaceuticals (Pte) Limited | Nouvelle formulation |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
US6569449B1 (en) | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
DE10102817B4 (de) | 2001-01-23 | 2006-01-12 | Lts Lohmann Therapie-Systeme Ag | Vorrichtung und Verfahren zur Hitzepulsgestützten transdermalen Applikation von Wirkstoffen |
DE10103158A1 (de) | 2001-01-24 | 2002-08-01 | Christian Von Falkenhausen | Vorrichtung zur elektrisch unterstützen Abgabe von Wirkstoffen aus flächenförmigen therapeutischen Systemen |
DE10105759C1 (de) | 2001-02-08 | 2001-10-25 | Lohmann Therapie Syst Lts | Vorrichtung zur elektrisch und magnetisch unterstützten Abgabe von Ladungsträgern in die Oberflächenschicht von Körpern |
WO2002068015A2 (fr) | 2001-02-22 | 2002-09-06 | Insulet Corporation | Dispositif modulaire et procede de perfusion |
JP2005506285A (ja) | 2001-02-27 | 2005-03-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然egfr阻害剤の使用 |
FR2822377A1 (fr) | 2001-03-23 | 2002-09-27 | Oreal | Utilisation de fibres comme agent anti-irritant dans une composition cosmetique ou dermatologique |
EP1372668B1 (fr) | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Methode permettant d'attenuer les reactions a des irritants cutanes |
CN101301275A (zh) | 2001-03-26 | 2008-11-12 | 史密丝克莱恩比彻姆公司 | 含烟碱的口服剂量形式的制备方法 |
CA2381630A1 (fr) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Methode de prevention de la dyskinesie |
SI2316439T1 (sl) | 2001-05-01 | 2015-10-30 | Euro-Celtique S.A. | Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid |
US20040019321A1 (en) | 2001-05-29 | 2004-01-29 | Sage Burton H. | Compensating drug delivery system |
SE0102197D0 (sv) | 2001-06-20 | 2001-06-20 | Pharmacia Ab | New product and use and manufacture thereof |
US6860731B2 (en) * | 2001-07-09 | 2005-03-01 | Asm Technology Singapore Pte Ltd. | Mold for encapsulating a semiconductor chip |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US6576269B1 (en) | 2001-09-06 | 2003-06-10 | Alexander Y. Korneyev | Treating open skin lesions using extract of sea buckthorn |
GB0121628D0 (en) | 2001-09-07 | 2001-10-31 | Watmough David J | Improved method and apparatus for transdermal drug delivery |
FR2829644A1 (fr) | 2001-09-10 | 2003-03-14 | St Microelectronics Sa | Procede securise de transmission de donnees multimedia |
US7615234B2 (en) | 2001-09-11 | 2009-11-10 | Glide Pharmaceutical Technologies Limited | Drug delivery technology |
US20060122577A1 (en) | 2001-09-26 | 2006-06-08 | Poulsen Jens U | Modular drug delivery system |
SE0103211D0 (sv) | 2001-09-27 | 2001-09-27 | Pharmacia Ab | New formulations and use thereof |
US6893655B2 (en) | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
US20030119879A1 (en) | 2001-10-15 | 2003-06-26 | Thomas Landh | Nicotine and chocolate compositions |
US20030087937A1 (en) | 2001-10-15 | 2003-05-08 | Nils-Olof Lindberg | Nicotine and cocoa powder compositions |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US20040037879A1 (en) | 2001-11-02 | 2004-02-26 | Adusumilli Prasad S. | Oral controlled release forms useful for reducing or preventing nicotine cravings |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
CN1325126C (zh) | 2001-11-16 | 2007-07-11 | 梅德创新股份公司 | 医药用的泵装置 |
US7311693B2 (en) | 2001-11-26 | 2007-12-25 | Nilimedix Ltd. | Drug delivery device and method |
US20040052843A1 (en) | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
SE0104388D0 (sv) | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
US6852741B2 (en) | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
CA2473541A1 (fr) * | 2002-01-16 | 2003-07-31 | Encapsulation Systems, Inc. | Dispositif de d'administration de substance |
JP2005518411A (ja) | 2002-01-16 | 2005-06-23 | エンド ファーマシューティカルズ インコーポレーテッド | 中枢神経系の障害を治療する製薬組成物及び方法 |
US20030159702A1 (en) | 2002-01-21 | 2003-08-28 | Lindell Katarina E.A. | Formulation and use manufacture thereof |
US7004928B2 (en) | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
US7392080B2 (en) | 2002-03-11 | 2008-06-24 | Altea Therapeutics Corporation | Transdermal drug delivery patch system, method of making same and method of using same |
US20070168501A1 (en) | 2002-03-29 | 2007-07-19 | Cobb Nathan K | Method and system for delivering behavior modification information over a network |
US6780171B2 (en) | 2002-04-02 | 2004-08-24 | Becton, Dickinson And Company | Intradermal delivery device |
JP2005526839A (ja) | 2002-04-23 | 2005-09-08 | アルザ・コーポレーシヨン | 不正使用の可能性が低い経皮鎮痛薬システム |
US7647099B2 (en) | 2002-04-29 | 2010-01-12 | Rocky Mountain Biosystems, Inc. | Controlled release transdermal drug delivery |
AU2003239433A1 (en) | 2002-05-13 | 2003-11-11 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20040166159A1 (en) | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
US7767698B2 (en) | 2002-06-03 | 2010-08-03 | Mcneil Ab | Formulation and use thereof |
KR20110120358A (ko) | 2002-06-10 | 2011-11-03 | 유로-셀티크 소시에떼 아노뉨 | 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템 |
KR100897890B1 (ko) | 2002-06-17 | 2009-05-18 | 인벤티아 헬스케어 피브이티. 엘티디. | 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법 |
US8586079B2 (en) | 2002-06-21 | 2013-11-19 | Graphic Productions Inc. | Promotional simulation for transdermal patch sampler |
US6975902B2 (en) | 2002-06-28 | 2005-12-13 | Alza Corporation | Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof |
US7196619B2 (en) | 2002-06-29 | 2007-03-27 | Neil Perlman | Habit cessation aide |
DE10240165A1 (de) | 2002-08-30 | 2004-03-18 | Disetronic Licensing Ag | Vorrichtung zum dosierten Ausstoßen eines flüssigen Wirkstoffes und Infusionspumpe |
CA2496798A1 (fr) | 2002-08-30 | 2004-03-11 | Alza Corporation | Construction de support multistratifiee pouvant etre alveolee et inscriptible |
US20040052851A1 (en) | 2002-09-16 | 2004-03-18 | Graff Allan H. | Modified release oral dosage form |
US20040259816A1 (en) | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
US7399401B2 (en) | 2002-10-09 | 2008-07-15 | Abbott Diabetes Care, Inc. | Methods for use in assessing a flow condition of a fluid |
US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
KR20050096922A (ko) | 2002-12-20 | 2005-10-06 | 니코노범 에이비 | 물리적 및 화학적으로 안정된 니코틴 함유 입자물질 |
US7887842B2 (en) | 2003-02-07 | 2011-02-15 | Teikoku Pharma Usa, Inc. | Methods of administering a dermatological agent to a subject |
AU2003900769A0 (en) | 2003-02-21 | 2003-03-13 | Francis Paul Galea | Medication and smoking cessation watch |
WO2004089299A2 (fr) | 2003-04-02 | 2004-10-21 | Advancis Pharmaceutical Corporation | Antigenes et adjuvants a administration transdermique pulsatile |
US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
SE0301320D0 (sv) | 2003-05-06 | 2003-05-06 | Astrazeneca Ab | Positive modulators of nicotinic acetylcholine receptors |
WO2004103283A2 (fr) | 2003-05-14 | 2004-12-02 | Pharmacia Corporation | Compositions comprenant un inhibiteur selectif de cyclooxygenase-2 et un stimulant de systeme nerveux central pour le traitement d'une lesion du systeme nerveux central |
US8021334B2 (en) | 2004-05-30 | 2011-09-20 | Nilimedix Ltd. | Drug delivery device and method |
US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
US20050048020A1 (en) | 2003-07-07 | 2005-03-03 | Wille John J. | Novel topical delivery system for plant derived anti-irritants |
DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
WO2005023227A2 (fr) | 2003-09-08 | 2005-03-17 | Pfizer Health Ab | Formulations de nicotine et leurs utilisations |
MXPA06004327A (es) | 2003-10-20 | 2007-01-26 | Teva Pharma | Composiciones y forma de dosificacion para el efecto retardado de levodopa. |
EP1527792A1 (fr) | 2003-10-27 | 2005-05-04 | Novo Nordisk A/S | Dispositif d'injection médicale montable sur la peau |
GEP20084561B (en) | 2003-10-28 | 2008-12-10 | Noven Pharma | System and method for controlled drug release and transdermal drug delivery device |
BRPI0416044A (pt) | 2003-11-13 | 2007-01-02 | Alza Corp | sistema e método para distribuição transdérmica |
US8589174B2 (en) | 2003-12-16 | 2013-11-19 | Adventium Enterprises | Activity monitoring |
US20050266032A1 (en) | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
US20050141346A1 (en) | 2003-12-30 | 2005-06-30 | Rawls David K. | Smoking cessation device |
US7867511B2 (en) | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
LT2351555T (lt) | 2004-02-23 | 2016-12-27 | Euro-Celtique S.A. | Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui |
IL160578A (en) | 2004-02-25 | 2013-11-28 | Newvaltech Knowledge Services And Invest Ltd | Remote training service and server |
PT1729730E (pt) | 2004-03-30 | 2009-04-06 | Euro Celtique Sa | Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso |
US20050226921A1 (en) | 2004-04-13 | 2005-10-13 | Kortzebom Robert N | Non-invasive analysis and controlled dosage transdermal active patch |
DE102004019916A1 (de) | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster |
DE102004022678A1 (de) | 2004-05-05 | 2005-12-15 | Humboldt-Universität Zu Berlin | Verfahren zum Regeln eines Volumenflusses einer Flüssigkeit in einer osmotischen Mikropumpe und osmotische Mikropumpe |
CN1332667C (zh) | 2004-05-26 | 2007-08-22 | 中国科学院生物物理研究所 | 一种抗帕金森症(pd)复合制剂 |
US7019622B2 (en) | 2004-05-27 | 2006-03-28 | Research In Motion Limited | Handheld electronic device including vibrator having different vibration intensities and method for vibrating a handheld electronic device |
WO2006004595A2 (fr) | 2004-05-28 | 2006-01-12 | Georgia Tech Research Corporation | Procedes et dispositifs destines a un traitement thermique |
US7537590B2 (en) | 2004-07-30 | 2009-05-26 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
EP1790375A4 (fr) | 2004-08-12 | 2009-06-17 | Hisamitsu Pharmaceutical Co | Appareil d'administration transdermique de médicament avec micro aiguille |
EP1802258A4 (fr) * | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | Administration de medicament transdermique biosynchrone |
DE102004044578A1 (de) | 2004-09-13 | 2006-03-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
EP1807033B1 (fr) | 2004-10-08 | 2016-07-20 | Noven Pharmaceuticals, Inc. | Dispositif d'administration transdermique de medicaments avec couche support occlusive |
WO2006041907A2 (fr) | 2004-10-08 | 2006-04-20 | Noven Pharmaceuticals, Inc. | Compositions et procedes d'administration d'oestradiol dans des systemes d'administration transdermiques de medicaments |
WO2006045221A1 (fr) | 2004-10-29 | 2006-05-04 | Chang-Ming Yang | Procede et dispositif pour surveiller la temperature, la respiration, les bruits cardiaques et l'etat de deglutition |
US8999356B1 (en) | 2004-12-03 | 2015-04-07 | Omp, Inc. | Drug delivery system |
WO2006066117A1 (fr) | 2004-12-17 | 2006-06-22 | Alza Corporation | Modulation de la temperature d'administration transdermique de medicaments |
AU2005319248A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
US8231573B2 (en) | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
EP1843812A4 (fr) | 2005-02-01 | 2008-12-03 | Intelliject Llc | Dispositifs, systemes et procedes pour administrer un medicament |
US20060188859A1 (en) | 2005-02-22 | 2006-08-24 | Haim Yakobi | Method and system for computer implemented personal counseling |
US20070042026A1 (en) | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
US8029927B2 (en) | 2005-03-22 | 2011-10-04 | Blue Spark Technologies, Inc. | Thin printable electrochemical cell utilizing a “picture frame” and methods of making the same |
US7955305B2 (en) | 2005-05-06 | 2011-06-07 | Medtronic Minimed, Inc. | Needle inserter and method for infusion device |
US8722233B2 (en) | 2005-05-06 | 2014-05-13 | Blue Spark Technologies, Inc. | RFID antenna-battery assembly and the method to make the same |
US8688189B2 (en) | 2005-05-17 | 2014-04-01 | Adnan Shennib | Programmable ECG sensor patch |
US8372040B2 (en) * | 2005-05-24 | 2013-02-12 | Chrono Therapeutics, Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
WO2007013975A2 (fr) | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Compositions et procedes destines a controler l'abus de medicaments |
US9687186B2 (en) | 2005-07-21 | 2017-06-27 | Steadymed Ltd. | Drug delivery device |
US8566121B2 (en) | 2005-08-29 | 2013-10-22 | Narayanan Ramasubramanian | Personalized medical adherence management system |
US20070086275A1 (en) | 2005-10-18 | 2007-04-19 | Robinson Robert J | Electronic reminder device |
JP4355722B2 (ja) | 2005-11-17 | 2009-11-04 | セイコーエプソン株式会社 | 流体輸送装置 |
CA2631435C (fr) | 2005-12-20 | 2014-08-12 | Antares Pharma, Inc. | Dispositif d'injection sans aiguille |
US20070149952A1 (en) | 2005-12-28 | 2007-06-28 | Mike Bland | Systems and methods for characterizing a patient's propensity for a neurological event and for communicating with a pharmacological agent dispenser |
EP1815919A1 (fr) * | 2006-02-03 | 2007-08-08 | Uponor Innovation Ab | Fabrication d'un produit allongé |
WO2008069970A2 (fr) | 2006-12-01 | 2008-06-12 | Aradigm Corporation | Formulations de nicotine, trousses, systèmes et procédés d'utilisation |
EP2125075A2 (fr) | 2007-01-22 | 2009-12-02 | Intelliject, Inc. | Injecteur médical équipé d'un système de détection et de surveillance de l'observance |
US20180110768A1 (en) | 2007-04-02 | 2018-04-26 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
GB2448224B (en) | 2007-04-02 | 2010-09-01 | Parkinson S Inst | Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
US20140207047A1 (en) | 2013-01-22 | 2014-07-24 | Chrono Therapeutics, Inc. | Transdermal drug delivery system and method |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
WO2018064377A1 (fr) | 2016-09-28 | 2018-04-05 | Chrono Therapeutics Inc. | Dispositif d'administration transdermique de médicament pour administrer des opioïdes |
AU2017373857A1 (en) | 2016-12-05 | 2019-06-13 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
WO2018129304A1 (fr) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Dispositifs et methodes d'administration transdermique de medicament |
WO2018148746A1 (fr) | 2017-02-13 | 2018-08-16 | Chrono Therapuetics Inc. | Dispositifs et procédés d'administration transdermique de medicament |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
-
2005
- 2005-09-13 EP EP05796698.8A patent/EP1802258A4/fr not_active Withdrawn
- 2005-09-13 WO PCT/US2005/032672 patent/WO2006031856A2/fr active Application Filing
- 2005-09-13 AU AU2005284908A patent/AU2005284908B2/en not_active Ceased
- 2005-09-13 US US11/162,517 patent/US20070191815A1/en not_active Abandoned
- 2005-09-13 JP JP2007531458A patent/JP5254616B2/ja active Active
- 2005-09-13 US US11/162,525 patent/US7780981B2/en active Active
- 2005-09-13 CA CA2580329A patent/CA2580329C/fr active Active
-
2010
- 2010-07-13 US US12/835,693 patent/US20100280432A1/en not_active Abandoned
-
2014
- 2014-01-23 US US14/162,156 patent/US20140200525A1/en not_active Abandoned
-
2015
- 2015-06-22 US US14/746,689 patent/US9555226B2/en active Active
- 2015-06-22 US US14/746,704 patent/US9555227B2/en active Active
-
2016
- 2016-12-20 US US15/385,638 patent/US10716764B2/en active Active
- 2016-12-20 US US15/385,665 patent/US20170100573A1/en not_active Abandoned
-
2020
- 2020-02-24 US US16/799,578 patent/US11471424B2/en active Active
- 2020-07-20 US US16/933,836 patent/US20210169822A1/en not_active Abandoned
Patent Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4545990A (en) * | 1982-11-22 | 1985-10-08 | L'oreal | Anti-acne composition |
US4708716A (en) * | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US4917895A (en) * | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
US5993435A (en) * | 1990-04-30 | 1999-11-30 | Alza Corporation | Device and method of iontophoretic drug delivery |
US5242941A (en) * | 1990-12-04 | 1993-09-07 | State Of Oregon | Methods of treating circadian rhythm disorders |
US5273756A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
US5352456A (en) * | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
US5820875A (en) * | 1991-10-10 | 1998-10-13 | Cygnus, Inc. | Device for administering drug transdermally with a controlled temporal change in skin flux |
US5370835A (en) * | 1991-11-21 | 1994-12-06 | Willi Sturtz Maschinenbau GmbH | Method of manufacturing rectangular frames |
US5389679A (en) * | 1992-01-21 | 1995-02-14 | Alliger; Howard | Method of treating small mouth ulcers with lactic acid |
US5405614A (en) * | 1992-04-08 | 1995-04-11 | International Medical Associates, Inc. | Electronic transdermal drug delivery system |
US5932240A (en) * | 1992-04-08 | 1999-08-03 | Americare Technology, Inc. | Multidose transdermal drug delivery system |
US5616332A (en) * | 1993-07-23 | 1997-04-01 | Herstein; Morris | Cosmetic skin-renewal-stimulating composition with long-term irritation control |
US5538503A (en) * | 1993-09-15 | 1996-07-23 | Henley; Julian L. | Programmable apparatus for reducing substance dependency in transdermal drug delivery |
US6090404A (en) * | 1994-01-13 | 2000-07-18 | Lts Lohmann Therapie-Systeme Gmbh | Estradiol penetration enhancers |
US6068853A (en) * | 1994-04-13 | 2000-05-30 | Novartis Corporation | Temporally controlled drug delivery systems |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5879322A (en) * | 1995-03-24 | 1999-03-09 | Alza Corporation | Self-contained transdermal drug delivery device |
US5785688A (en) * | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
US6129702A (en) * | 1996-12-03 | 2000-10-10 | Fraunhofer-Gesellschaft Zur Forderung Angewandten Forschung E.V. | Medicament dosing system |
US6165155A (en) * | 1997-02-07 | 2000-12-26 | Sarcos, Lc | Multipathway electronically-controlled drug delivery system |
US6374136B1 (en) * | 1997-12-22 | 2002-04-16 | Alza Corporation | Anhydrous drug reservoir for electrolytic transdermal delivery device |
US6595956B1 (en) * | 1998-03-23 | 2003-07-22 | Joseph Gross | Drug delivery device |
US6214379B1 (en) * | 1998-04-02 | 2001-04-10 | Kv Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
US6211296B1 (en) * | 1998-11-05 | 2001-04-03 | The B. F. Goodrich Company | Hydrogels containing substances |
US6539250B1 (en) * | 1999-12-15 | 2003-03-25 | David S. Bettinger | Programmable transdermal therapeutic apparatus |
US6638528B1 (en) * | 2000-01-20 | 2003-10-28 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6887202B2 (en) * | 2000-06-01 | 2005-05-03 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US20050182307A1 (en) * | 2000-06-01 | 2005-08-18 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US20020127256A1 (en) * | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
US6723086B2 (en) * | 2001-05-07 | 2004-04-20 | Logiq Wireless Solutions, Inc. | Remote controlled transdermal medication delivery device |
US20030065294A1 (en) * | 2001-09-28 | 2003-04-03 | Pickup Ray L. | Cutaneous administration system |
US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
US6861066B2 (en) * | 2002-03-11 | 2005-03-01 | Health Plus International Inc. | Method for the delivery of a biologically active agent |
US20040138074A1 (en) * | 2002-05-01 | 2004-07-15 | Nawaz Ahmad | Warming and nonirritating lubricant compositions and method of comparing irritation |
US20050034842A1 (en) * | 2003-08-11 | 2005-02-17 | David Huber | Electroosmotic micropumps with applications to fluid dispensing and field sampling |
US20050238704A1 (en) * | 2003-10-27 | 2005-10-27 | Werner Zumbrunn | Transdermal drug delivery method and system |
US20050151110A1 (en) * | 2004-01-14 | 2005-07-14 | Minor Barbara H. | Fluoroether refrigerant compositions and uses thereof |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9555226B2 (en) | 2003-10-27 | 2017-01-31 | Chrono Therapeutics Inc. | Transdermal drug delivery method and system |
US10716764B2 (en) | 2003-10-27 | 2020-07-21 | Morningside Venture Investments Limited | Transdermal drug delivery method and system |
US8741336B2 (en) | 2004-09-13 | 2014-06-03 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US7780981B2 (en) * | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US11471424B2 (en) | 2004-09-13 | 2022-10-18 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
US10258778B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20060062838A1 (en) * | 2004-09-13 | 2006-03-23 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US10258738B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20080220092A1 (en) * | 2004-09-13 | 2008-09-11 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US9555227B2 (en) | 2004-09-13 | 2017-01-31 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
US9669199B2 (en) | 2004-09-13 | 2017-06-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20100280432A1 (en) * | 2004-09-13 | 2010-11-04 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
USRE46217E1 (en) | 2005-05-24 | 2016-11-29 | Chrono Therapeutics Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
US20100169260A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
US9750903B2 (en) | 2008-12-30 | 2017-09-05 | Gearbox, Llc | Method for administering an inhalable compound |
US9724483B2 (en) | 2008-12-30 | 2017-08-08 | Gearbox, Llc | Method for administering an inhalable compound |
US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
US10232156B2 (en) | 2015-01-28 | 2019-03-19 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
US12011560B2 (en) | 2015-01-28 | 2024-06-18 | Morningside Venture Investments Limited | Drug delivery methods and systems |
US11400266B2 (en) | 2015-01-28 | 2022-08-02 | Morningside Venture Investments Limited | Drug delivery methods and systems |
US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
US12017029B2 (en) | 2018-05-29 | 2024-06-25 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Also Published As
Publication number | Publication date |
---|---|
US20170100572A1 (en) | 2017-04-13 |
US20200330369A1 (en) | 2020-10-22 |
US20210169822A1 (en) | 2021-06-10 |
CA2580329C (fr) | 2015-01-06 |
AU2005284908A1 (en) | 2006-03-23 |
AU2005284908B2 (en) | 2011-12-08 |
US20170100573A1 (en) | 2017-04-13 |
US9555227B2 (en) | 2017-01-31 |
US10716764B2 (en) | 2020-07-21 |
US20060062838A1 (en) | 2006-03-23 |
WO2006031856A2 (fr) | 2006-03-23 |
JP2008512215A (ja) | 2008-04-24 |
US20100280432A1 (en) | 2010-11-04 |
US20150283366A1 (en) | 2015-10-08 |
JP5254616B2 (ja) | 2013-08-07 |
US20140200525A1 (en) | 2014-07-17 |
EP1802258A2 (fr) | 2007-07-04 |
CA2580329A1 (fr) | 2006-03-23 |
US20150283367A1 (en) | 2015-10-08 |
US9555226B2 (en) | 2017-01-31 |
EP1802258A4 (fr) | 2015-09-23 |
US7780981B2 (en) | 2010-08-24 |
WO2006031856A3 (fr) | 2006-08-17 |
US11471424B2 (en) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11471424B2 (en) | Biosynchronous transdermal drug delivery | |
US10258738B2 (en) | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | |
JP5925844B2 (ja) | 抗片頭痛化合物の送達のための経皮的方法およびシステム | |
US20140207047A1 (en) | Transdermal drug delivery system and method | |
CA2668184A1 (fr) | Techniques d'administration transdermique pour des medicaments, des nutraceutiques et d'autres substances actives | |
Zaffaroni | Systems for controlled drug delivery | |
AU2015203213B2 (en) | Transdermal methods and systems for the delivery of anti-migraine compounds | |
AU2012261753A1 (en) | Transdermal methods and systems for the delivery of anti-migraine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CHRONO THERAPEUTICS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DIPIERRO, GUY;REEL/FRAME:017322/0577 Effective date: 20051129 |
|
AS | Assignment |
Owner name: CHRONO THERAPEUTICS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DIPIERRO, GUY;REEL/FRAME:022943/0591 Effective date: 20090706 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: MORNINGSIDE VENTURE INVESTMENTS LIMITED, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CTI (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC;REEL/FRAME:055382/0388 Effective date: 20200408 Owner name: CTI (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHRONO THERAPEUTICS, INC.;REEL/FRAME:055384/0227 Effective date: 20191021 |